Linagliptin Stada

Linagliptin, the active ingredient in Linagliptin Stada, is a dipeptidyl peptidase-4 (DPP-4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults. GNH USA supplies Linagliptin Stada as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin Stada belongs to the DPP-4 inhibitor class and is used to improve glycaemic control in type 2 diabetes. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels. - Type 2 diabetes mellitus (combined with metformin): enhances overall glycaemic control when added to metformin therapy. - Type 2 diabetes mellitus (combined with insulin): may allow reduction of insulin dose while maintaining target glucose levels.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient mild to moderate head pain. - Upper respiratory tract infection: symptoms such as cough, sore throat, or congestion. - Dizziness: occasional light‑headed sensation. Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe hypersensitivity reactions: rash, angioedema, or anaphylaxis. - Bullous pemphigoid: rare autoimmune skin blistering condition.

Linagliptin Stada should be used with consideration of the following precautions. - Renal impairment: assess renal function before initiating therapy. - Hepatic impairment: monitor liver enzymes periodically. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Pregnancy and lactation: prescribe only if potential benefit outweighs risk. - Drug interactions: review concomitant medications for possible interactions. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Linagliptin Stada may interact with several medicines. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - CYP3A4 inducers (e.g., rifampin): may reduce linagliptin efficacy. Moderate Interactions (Monitor Closely): - Diuretics: monitor for enhanced hypoglycaemic effect. - Insulin or insulin secretagogues: dose adjustment may be required to avoid hypoglycaemia. - Other DPP‑4 inhibitors: concurrent use is not recommended.